HMH partners with Neosoma for innovation in brain tumor treatment, research

Hackensack Meridian Health and Neosoma Inc., an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers through the use of artificial intelligence, recently announced a new strategic partnership to tackle some of the most difficult-to-treat tumors.

The collaboration will include clinical data sharing, clinical research and strategic investment from the health network to support the Massachusetts-based company’s innovative method of imaging, tracking and collecting data on numerous types of brain tumors, including glioblastomas.

“We are committed to investing in research and innovative therapies to live our mission to transform health care and give our patients the best possible outcomes,” Robert Garrett, CEO of Hackensack Meridian Health, said. “Partnering with Neosoma Inc. is a great way to continue to develop potential game-changing therapies to treat these challenging cancers.”

“We have a terrific partnership with Hackensack Meridian Health already,” Ken Kolodziej, the co-founder and CEO of Neosoma, said. “We’re very excited to expand the scope of our collaboration with the shared goal of improving treatment and outcomes for patients with brain cancer.”

The partnership will include HMH physicians using Neosoma’s software in clinical practice, starting with Hackensack Meridian JFK University Medical Center; physician input and feedback for development of future software, including neurosurgeons, neuro-oncologists, neuroradiologists, radiation oncologists and other clinicians; and data sharing for product research & development efforts, including collaboration with Anthology Diagnostics for genomics data and capabilities, among other benefits.

Neosoma recently received U.S. Food and Drug Administration 510(k) clearance for its first AI-based neuro-oncology software device, Neosoma HGG. The technology produces precise and accurate brain tumor analysis on MRIs, providing physicians with critical insights to guide treatment decisions.

The Neosoma technology will help physicians to better plan procedures, assess post-procedural results, guide chemo and immunotherapy treatments, track patients longitudinally, support an improved patient experience and help lead to improved treatment, according to the company.

“Neosoma helps to avoid interruptions in care, unnecessary surgeries and unnecessary changes in therapy,” Dr. Joseph Landolfi, a neuro-oncologist and also the chief medical officer at JFK University Medical Center, said. “The entire team benefits from centralized information, more efficient communication and treatment protocols tailored to each specific patient.”